Contac cold medicine hasn’t disappeared entirely, but it’s a fundamentally different product than the one millions of Americans relied on from the 1960s through the early 2000s. The original formula was pulled from shelves in 2000 after its key decongestant ingredient was linked to a risk of bleeding in the brain. What’s sold under the Contac name today bears little resemblance to the iconic capsule filled with “tiny time pills.”
The Original Contac and Its Signature Design
Contac launched as one of the first extended-release cold medicines available over the counter. Its clear capsule was packed with hundreds of tiny colored beads, each designed to dissolve at a different rate so the medication would release gradually over several hours. This “tiny time pills” concept was heavily marketed and became synonymous with the brand. The active decongestant in the original formula was phenylpropanolamine, commonly called PPA, a stimulant that narrowed blood vessels in the nasal passages to relieve congestion.
PPA wasn’t unique to Contac. It was found in dozens of over-the-counter cold remedies and diet pills throughout the 1980s and 1990s. But Contac was one of the most recognizable names built around the ingredient.
Why the Original Formula Was Pulled
In November 2000, the FDA issued a public health advisory warning that phenylpropanolamine was associated with hemorrhagic stroke, a type of bleeding inside the brain. The warning came after the results of the Yale Hemorrhagic Stroke Project, a major study that found an increased risk of stroke among people using PPA. The risk was detected in women using the drug both for nasal decongestion and for weight control, particularly in the first three days after starting it.
An FDA advisory committee reviewed the Yale data and concluded that PPA could not be considered safe for continued use. The FDA acknowledged that the absolute risk of hemorrhagic stroke from PPA was very low for any individual, but it determined that the conditions these products treated (stuffy noses, basically) did not justify even a small increased risk of such a serious event. Manufacturers were asked to reformulate their products, and PPA was effectively removed from the U.S. market.
The Reformulation Shuffle
Contac’s manufacturer, SmithKline Beecham (later GlaxoSmithKline), initially pointed consumers toward versions of the product that already contained pseudoephedrine, a different decongestant considered safe. Pseudoephedrine is an effective nasal decongestant, but it created a new problem: it can be used to manufacture methamphetamine. Beginning in 2006, federal law required pseudoephedrine products to be kept behind the pharmacy counter, with purchase limits and ID requirements.
That regulatory shift pushed many cold medicine manufacturers, including Contac’s makers, to switch yet again. This time they moved to phenylephrine, a decongestant that didn’t have the meth-production concern and could remain on open store shelves. So within about six years, Contac’s core decongestant ingredient changed twice.
What Contac Looks Like Today
The current product, sold as Contac Cold + Flu, comes in a day/night caplet format. The daytime formula contains acetaminophen (a pain reliever and fever reducer) and phenylephrine (the decongestant). The nighttime formula adds chlorpheniramine, an antihistamine to help with sneezing and runny nose. Gone are the iconic clear capsules with tiny time beads. The product is now standard caplets, taken two at a time every six hours.
It’s a generic-looking combination cold product that competes with dozens of nearly identical formulas on the shelf. The brand name is really the only thread connecting it to the original.
The Phenylephrine Problem
There’s an uncomfortable wrinkle in the current Contac story. In 2023, an FDA advisory committee unanimously concluded that oral phenylephrine, the decongestant now at the heart of Contac Cold + Flu, does not work as a nasal decongestant at the doses found in over-the-counter products. The committee reviewed extensive data and determined that there is no scientific support for its effectiveness when swallowed in pill form. (Phenylephrine does work as a nasal spray, but that’s a different delivery method.)
Following that unanimous vote, the FDA proposed removing oral phenylephrine from the list of ingredients recognized as safe and effective for OTC use. If finalized, this ruling would force yet another reformulation of Contac and hundreds of other cold medicines that rely on the same ingredient. The process is still unfolding, but the writing is on the wall: the decongestant in today’s Contac likely doesn’t do much for a stuffy nose.
Why You Can’t Find the “Real” Contac
If you remember Contac working well in the 1990s, that’s because PPA was a genuinely effective decongestant. Its replacement, pseudoephedrine, also works well but is now locked behind the pharmacy counter under a different set of brand names. The version of Contac sitting on store shelves today contains a decongestant that a panel of FDA experts says is no better than a placebo when taken orally.
The brand has also changed corporate hands multiple times, further diluting its identity. What was once a flagship product from a major pharmaceutical company is now a legacy name applied to a formula that has been reshaped by two decades of ingredient bans, drug policy changes, and regulatory challenges. For shoppers who remember the original, the name on the box is about all that’s left.